Related Experiment Video
Updated: Aug 14, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
Published on: January 19, 2019
Muscle cells produce a low molecular weight factor with anti-cancer activity
M Djaldetti1, B Sredni, R Zigelman
1Electron Microscopy Unit, Hasharon Hospital, Rabin Medical Center, Petach-Tiqva, Israel.
Abstract:
The present study describes a new low molecular weight factor released by muscle cells, which inhibits proliferation of tumor cells in vitro and in vivo, is highly specific towards tumor cells, and has no observable effect on normal cells' proliferation. What first prompted us to investigate this factor was the observation that tumor metastases are extremely rare in striated muscles. Co-culturing of striated muscle cells with malignant cells led to marked morphological alterations in the latter, in contrast to the same cells when incubated without muscle cells. A conditioned medium of striated muscle cells was prepared and its effect tested on a variety of cells. This conditioned medium (CM) inhibited proliferation of tumor cell lines of murine (B16 melanoma, Madison 109 lung carcinoma, MCA-105 sarcoma, ESB lymphoma), or of human origin (HTB-38 adenocarcinoma, T47D breast carcinoma, CX1 colon carcinoma). The proliferation of normal cells (bone marrow cells, fetal liver erythroid cells) was not affected by the CM. Flow cytometric analysis of B16 melanoma cells following incubation with the CM revealed that 63% +/- 12 of the cells were in the G0/G1 phase of the cell cycle, compared to 47.8% +/- 8 of cells incubated with a medium (not conditioned) only. The activity of the CM and of certain fractions thereof was also demonstrated in vivo: they prevented tumor growth in mice inoculated intraperitoneally with MCA-105 sarcoma cells. Partial purification of the CM revealed that the active component was a non-proteinaceous compound with a molecular weight of about 500 D. The results clearly suggest that muscle cells produce a low molecular weight factor which can selectively inhibit the proliferation of tumor cells in vitro and in vivo. This factor is neither species nor tumor specific.
Insights
Muscle cells release a novel, low molecular weight factor that selectively inhibits tumor cell proliferation both in vitro and in vivo. This discovery offers a new avenue for cancer research and potential therapeutic strategies.
Area of Science:
- Biochemistry
- Cell Biology
- Oncology
Background:
- Tumor metastases are notably rare in striated muscles.
- Muscle cells induce morphological changes in malignant cells upon co-culture.
Purpose of the Study:
- To identify and characterize a factor from muscle cells that inhibits tumor cell proliferation.
- To investigate the specificity and mechanism of action of this muscle-derived factor.
Main Methods:
- Preparation of conditioned medium (CM) from striated muscle cells.
- In vitro proliferation assays using various murine and human tumor cell lines and normal cells.
- In vivo tumor growth inhibition studies in mice.
- Flow cytometry to analyze cell cycle phase distribution.
- Partial purification to determine the nature of the active component.
Main Results:
- CM significantly inhibited proliferation of diverse tumor cell lines but not normal cells.
- Flow cytometry showed CM induced G0/G1 cell cycle arrest in B16 melanoma cells.
- CM administration in vivo prevented tumor growth in mice inoculated with sarcoma cells.
- The active factor is a non-proteinaceous compound with a molecular weight of approximately 500 D.
Conclusions:
- Muscle cells produce a low molecular weight factor that selectively inhibits tumor cell proliferation.
- This factor demonstrates potential as a novel anti-tumor agent, effective both in vitro and in vivo.
- The factor's non-proteinaceous nature and low molecular weight suggest distinct biochemical properties for further investigation.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

